Glaxo Group Limited

Duncan B Judd

John W Clitherow

John Bradshaw

Barry J Price

Michael Martin-Smith

Harry Finch

Eric W Collington

John W MacKinnon

Michael D Dowle

Roger Hayes

David I Scopes

Lee Andrew Harrison

Suzanne Elaine Keeling

Barry C Ross

David Middlemiss

Colin David Eldred

Stephen Swanson

Xiao Qing Lewell

Simon Teanby Hodgson

Caroline Mary Cook

Kevin S Cardwell

Paul Martin Gore

Torquil I Jack

Graeme Michael Robertson

Alan Naylor

David E Bays

Linda Carey

John W Mackinnon

Rachael Anne Ancliff

James D Meadows

Stephen Paul Watson

John G Montana

Malcolm Johnson

Andrew John Walker

Mark Wilkinson

Martin Pass

Andrew Pearce

Peter Strong

Dearg S Brown

Rachael Ann Ancliff

Martin Alistair Hayes

Gail Mills

David J Belton

Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases

There are provided according to the invention, novel compounds of formula (I) wherein R, R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Compounds useful in the treatment of inflammatory diseases

The present invention relates to novel morpholin-acetamide compounds of formula (I) useful for the treatment of inflammatory diseases. Compounds of formula (I)wherein R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Morpholin-acetamide derivatives for the treatment of inflammatory diseases

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein the R groups are defined in the specification. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.

Benzofuran derivatives

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt, solvate or metabolically labile ester thereof wherein

Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents --COR.sub.4, --CO.sub.2 R.sub.4, --COCO.sub.2 R.sub.4 or --CONR.sub.4 R.sub.5 (where R.sub.4 and R.sub.5 may be the same or different and represent a hydrogen atom or a C.sub.1-3 alkyl group);

Chemical compounds

Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents hydrogen, unsubstituted or substituted C.sub.1-6 alkyl, halogen, --COR.sub.4 or --CO.sub.2 R.sub.4 (where R.sub.4 represents hydrogen or unsubstituted or substituted C.sub.1-6 alkyl);

Pharmaceutically useful furo[3,2-c]pyridines

Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents --COR.sub.4, --CO.sub.2 R.sub.4 or --COCO.sub.2 R.sub.4 (where R.sub.4 represents a hydrogen atom or an unsubstituted or substituted C.sub.1-10 hydrocarbon moiety);

Piperazine compounds

The use is described of both (i) a systemic non-steroidal anti-inflammatory drug and (ii) a compound of formula (1) ##STR1## wherein n is 1 or 2;

Anti-inflammatory compositions comprising a systemic non-steroidal

Compounds are described of formula ##STR1## wherein n is 1 or 2;

Cyclopentyl ethers and their preparation and pharmaceutical formulation

Compounds are described of formula (1) ##STR1## wherein m is 1 to 4;

The use is described of compounds of formula ##STR1## in which n is 1 or 2;

Cyclopentyl ethers and their use in medicine

Compounds are described of formula (I) ##STR1## in which n is 1 or 2;

Growing community of inventors

Ware, United Kingdom

Duncan B Judd